Fresenius Taps China’s WuXi to Expand Biosimilar Drug Portfolio
Fresenius SE agreed to partner with Chinese contract drug developer WuXi Biologics on biosimilar candidates that could reach the market in the next decade, potentially more than doubling its current portfolio.
We haven't written up this one. Bloomberg has the full story — the link below goes straight to it.